简介：

简介：我在东半球，你在西半球；他在北半球，她在南半球……你是不是很好奇，“地球村”里那些未曾谋面的同龄人，有着怎样多姿多彩的生活？他们是不是都有着自己独特的语言、文化和习俗？从本期开始，我们将一起穿越到世界的不同地方，去看、去听、去感受……

简介：

简介：ＬｈａｓａｎｓｌｅａｄｉｎｇＡＭｏｄｅｒｎＬｉｆｅＤＯＱＵＮＯｎｅｍｏｒｎｉｎｇ，Ｌｈａｓａｃｉｔｉｚｅｎｓｗｏｋｅｕｐｔｏｆｉｎｄｓｕｓｐｅｎｓｉｏｎｏｆｔｈｅｉｒｅｌｅｃｔｒｉｃａｌｓｕｐｐｌｙ．Ｎｏｒａｄｉｏｎｅｗｓ．ＮｏＴＶｐｒｏｇｒａｍｓ．...

简介：

简介：Atierschoolwasover,Iranallthewayhome.MumwaseookingwhenIgothome.“I'mhungry,Mum.MayIhavesomethingtoeat?”“Oh,waitaminute.Supperwillbereadvsoon.Andsomeguestswillcomefordinnertoday.

简介：

简介：

简介：

简介：大家好!我叫梅西亚，生活在巴西。我10岁了，4年后毕业。在巴西，孩子们从7岁到14岁上学。我们每天只上4个小时的课。

简介：

简介：

简介：

简介：我们有时烦恼，有时忧伤，有时谴责生活的不公平，生活对于我们到底意味着什么，读过此文，你会懂得许多……

简介：中国的春节，日本的成人节以及西方的情人节在这个寒冷的假期把温暖，甜蜜的生活带到我们的身边。

简介：

简介：AbstractType 2 diabetes mellitus and metabolic disorders have become an epidemic globally. However, the pathogenesis remains largely unclear and the prevention and treatment are still limited. In addition to environmental factors during adulthood, early life is the critical developmental window with high tissue plasticity, which might be modified by external environmental cues. Substantial evidence has demonstrated the vital role of early-life nutrition in programming the metabolic disorders in later life. In this review, we aim to overview the concepts of fetal programming and investigate the effects of early-life nutrition on energy metabolism in later life and the potential epigenetic mechanism. The related studies published on PubMed database up to March 2020 were included. The results showed that both maternal overnutrition and undernutrition increased the riskes of metabolic disorders in offspring and epigenetic modifications, including DNA methylation, miRNAs, and histone modification, might be the vital mediators. The beneficial effects of early-life lifestyle modifications as well as dietary and nutritional interventions on these deleterious metabolic remolding were initially observed. Overall, characterizing the early-life malnutrition that reshapes metabolic disease trajectories may yield novel targets for early prevention and intervention and provide a new point of view to the energy metabolism.

简介：GrandpaQin,now74,hasreturnedtowherehehadlivedformorethansixdecadesinthecompanyofhisdaughter.Infrontofhim,theolddilapidatedsceneshavealldisappeared.Theformernine1.9-meter-widelaneshavebecome12six-meter-wideroads.Theformercrowdedcourtyards,11stairsdownthelanes,havecompletelychangedtheiroutlook.TheonlythingsthatseemtohavenotchangedaretheoldBeijingstyleofbluetilesandgraybricksandtheimperialcitywallsnearbythatarethewitnessestoallthesechanges.GrandpaQinisamongthe300householdswhohavereturnedaftertherebuildingprojectwascompleted.Qin’sfamilylivedintheNanchizicommunityforfivegenerations.Thebig

简介：无

简介：AbstractBackground:There were few studies on real-world data about autologous hematopoietic stem cell transplantation (auto-HSCT) or allogeneic HSCT (allo-HSCT) in peripheral T-cell lymphoma (PTCL). This study aimed to investigate the clinical outcomes of patients who received auto-HSCT or allo-HSCT in China.Methods:From July 2007 to June 2017, a total of 128 patients who received auto-HSCT (n = 72) or allo-HSCT (n = 56) at eight medical centers across China were included in this study. We retrospectively collected their demographic and clinical data and compared the clinical outcomes between groups.Results:Patients receiving allo-HSCT were more likely to be diagnosed with stage III or IV disease (95% vs. 82%, P = 0.027), bone marrow involvement (42% vs. 15%, P= 0.001), chemotherapy-resistant disease (41% vs. 8%, P= 0.001), and progression disease (32% vs. 4%, P < 0.001) at transplantation than those receiving auto-HSCT. With a median follow-up of 30 (2-143) months, 3-year overall survival (OS) and progression-free survival (PFS) in the auto-HSCT group were 70%(48/63) and 59%(42/63), respectively. Three-year OS and PFS for allo-HSCT recipients were 46%(27/54) and 44%(29/54), respectively. There was no difference in relapse rate (34%[17/63] in auto-HSCT vs. 29%[15/54] in allo-HSCT, P = 0.840). Three-year non-relapse mortality rate in auto-HSCT recipients was 6%(4/63) compared with 27%(14/54) for allo-HSCT recipients (P = 0.004). Subanalyses showed that patients with lower prognostic index scores for PTCL (PIT) who received auto-HSCT in an upfront setting had a better outcome than patients with higher PIT scores (3-year OS: 85% vs. 40%, P = 0.003). Patients with complete remission (CR) undergoing auto-HSCT had better survival (3-year OS: 88% vs. 48% in allo-HSCT, P = 0.008). For patients beyond CR, the outcome of patients who received allo-HSCT was similar to that in the atuo-HSCT group (3-year OS: 51% vs. 46%, P = 0.300).Conclusions:Our study provided real-world data about auto-HSCT and allo-HSCT in China. Auto-HSCT seemed to be associated with better survival for patients in good condition (lower PIT score and/or better disease control). For patients possessing unfavorable characteristics, the survival of patients receiving allo-HSCT group was similar to that in the auto-HSCT group.